Subscribe

Study Summaries

Korean HIPEC trial - IDS patients only 2023

HIPEC combined with ICS significantly improved PFS and OS in advanced-stage ovarian cancer patients, without increasing the rate of severe postoperative complications. A notable reduction in peritoneal recurrence may contribute to the OS improvement.

Korean HIPEC Trial: HIPEC After Primary or Interval Cytoreductive Surgery in Ovarian Cancer

The addition of HIPEC after interval cytoreductive surgery following neoadjuvant chemotherapy provided significant improvements in PFS and OS.

Interlace Trial

Induction chemotherapy followed by chemoradiotherapy significantly improves both progression-free survival and overall survival in patients with locally advanced cervical cancer compared to chemoradiotherapy alone.

COMPASSION-16: Cadonilimab for Persistent, Recurrent, or Metastatic Cervical Cancer

Cadonilimab potentially offers better PFS than pembrolizumab and atezolizumab therapies in recurrent advanced metastatic cervical cancer

mEOC/GOG-0241: Oxaliplatin-Capecitabine vs. Carboplatin-Paclitaxel in Mucinous Epithelial Ovarian Cancer

Neither oxaliplatin-capecitabine nor bevacizumab significantly improved OS or PFS compared to paclitaxel-carboplatin in advanced-stage mucinous ovarian cancer.

GOG 205: Chemoradiation for Locally Advanced Vulvar Cancer

The combination of radiation therapy with weekly cisplatin chemotherapy is effective in achieving high complete clinical and pathological response rates with manageable toxicity for the treatment of locally-advanced vulvar carcinoma.

Westin LNG-IUD Phase II (2021): Levonorgestrel IUD for Complex Atypical Hyperplasia and Early Endometrial Cancer

GOG 173: Sentinel Lymph Node Biopsy in Vulvar Cancer

MILO/ENGOT-ov11: Binimetinib in Recurrent Low-Grade Serous

In low-grade serous ovarian cancer, Binimetinib did not significantly improve PFS compared to standard of care chemotherapy.

SOC-1: Secondary Cytoreduction in Platinum-Sensitive Relapsed Ovarian Cancer

Surgery did not improve overall survival, but it showed a benefit in certain analyses. This supports the potential efficacy of secondary cytoreduction in specialized centers and for selected patients.